دورية أكاديمية
Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
| العنوان: | Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth. |
|---|---|
| المؤلفون: | Cao MN; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Zhou YB; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Electronic address: ybzhou@mail.shcnc.ac.cn., Gao AH; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Cao JY; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Gao LX; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Sheng L; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Xu L; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Su MB; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Cao XC; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Han MM; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China., Wang MK; Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China., Li J; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Electronic address: jli@mail.shcnc.ac.cn. |
| المصدر: | Biochimica et biophysica acta [Biochim Biophys Acta] 2014 Jun; Vol. 1840 (6), pp. 2004-13. Date of Electronic Publication: 2014 Feb 15. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Pub. Co Country of Publication: Netherlands NLM ID: 0217513 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0006-3002 (Print) Linking ISSN: 00063002 NLM ISO Abbreviation: Biochim Biophys Acta Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam : Elsevier Pub. Co. |
| مواضيع طبية MeSH: | Boronic Acids/*therapeutic use , Diterpenes/*pharmacology , Jatropha/*chemistry , Multiple Myeloma/*drug therapy , Proteasome Inhibitors/*pharmacology , Pyrazines/*therapeutic use , Reactive Oxygen Species/*metabolism , Ubiquitin-Specific Proteases/*antagonists & inhibitors, Apoptosis/drug effects ; Bortezomib ; Cell Line, Tumor ; Humans ; Multiple Myeloma/pathology |
| مستخلص: | Background: Ubiquitin-proteasome pathway (UPP) plays a very important role in the degradation of proteins. Finding novel UPP inhibitors is a promising strategy for treating multiple myeloma (MM). Methods: Ub-YFP reporter assays were used as cellular UPP models. MM cell growth, apoptosis and overall death were evaluated with the MTS assay, Annexin V/PI dual-staining flow cytometry, poly (ADP-ribose) polymerase (PARP) cleavage, and PI uptake, respectively. The mechanism of UPP inhibition was analyzed by western blotting for ubiquitin, in vitro and cellular proteasomal and deubiquitinases (DUBs) activity assays. Cellular reactive oxygen species (ROS) were measured with H2DCFDA. Results: Curcusone D, identified as a novel UPP inhibitor, causes cell growth inhibition and apoptosis in MM cells. Curcusone D induced the accumulation of poly-ubiquitin-conjugated proteins but could not inhibit proteasomal activity in vitro or in cells. Interestingly, the mono-ubiquitin level and the total cellular DUB activity were significantly downregulated following curcusone D treatment. Furthermore, curcusone D could induce ROS, which were closely correlated with DUB inhibition that could be nearly completely reversed by NAC. Finally, curcusone D and the proteasomal inhibitor bortezomib showed a strong synergistic effect against MM cells. Conclusions: Curcusone D is novel UPP inhibitor that acts via the ROS-induced inhibition of DUBs to produce strong growth inhibition and apoptosis of MM cells and synergize with bortezomib. General Significance: The anti-MM molecular mechanism study of curcusone D will promote combination therapies with different UPP inhibitors against MM and further support the concept of oxidative stress regulating the activity of DUBs. (Copyright © 2014 Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Bortezomib; Curcusone D; Deubiquitinase; Multiple myeloma; ROS; Ubiquitin–proteasome pathway |
| المشرفين على المادة: | 0 (Boronic Acids) 0 (Diterpenes) 0 (Proteasome Inhibitors) 0 (Pyrazines) 0 (Reactive Oxygen Species) 0 (curcusone D) 69G8BD63PP (Bortezomib) EC 3.4.19.12 (Ubiquitin-Specific Proteases) |
| تواريخ الأحداث: | Date Created: 20140219 Date Completed: 20140703 Latest Revision: 20161126 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.bbagen.2014.02.006 |
| PMID: | 24534329 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0006-3002 |
|---|---|
| DOI: | 10.1016/j.bbagen.2014.02.006 |